Literature DB >> 1940276

Microbial growth and endotoxin production in the intravenous anesthetic propofol.

M J Arduino1, L A Bland, S K McAllister, S M Aguero, M E Villarino, M M McNeil, W R Jarvis, M S Favero.   

Abstract

OBJECTIVE: In this study, we measured microbial growth and endotoxin production in the intravenous anesthetic propofol using 10 different microbial strains; 6 isolated from outbreak cases and 4 from laboratory stock cultures.
DESIGN: In each trial, endotoxin-free glass tubes containing 10 ml propofol were inoculated with 10(0)-10(3) CFU/ml of the test organism and incubated at 30 degrees C for 72 hours.
SETTING: In May and June 1990, the Centers for Disease Control received reports of 5 outbreaks in 5 states of postsurgical patient infections and/or pyrogenic reactions. Epidemiologic and laboratory investigations implicated extrinsic contamination of an intravenous anesthetic, propofol, as the probable source of these outbreaks.
RESULTS: After 24 hours, 9 of the 10 cultures increased in viable counts by 3 to 6 logs. At least 1 ng/ml of endotoxin was produced within 24 hours by Escherichia coli, Enterobacter cloacae, and Acinetobacter calcoaceticus subspecies anitratus.
CONCLUSIONS: Propofol can support rapid microbial growth and endotoxin production. To avoid infectious complications, scrupulous aseptic technique should be used when preparing or administering this anesthetic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940276     DOI: 10.1086/646405

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

Review 1.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Postsurgical Candida albicans infections associated with an extrinsically contaminated intravenous anesthetic agent.

Authors:  M M McNeil; B A Lasker; T J Lott; W R Jarvis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  Practical infection control.

Authors:  A J Berry
Journal:  Can J Anaesth       Date:  1995-11       Impact factor: 5.063

4.  The use of neuromuscular blocking drugs in the intensive care unit: a US perspective.

Authors:  M J Murray; R A Strickland; C Weiler
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 5.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 6.  Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.

Authors:  B Fulton; E M Sorkin
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

7.  Propofol emulsion and bacterial contamination.

Authors:  G J McHugh; G M Roper
Journal:  Can J Anaesth       Date:  1995-09       Impact factor: 5.063

8.  Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.

Authors:  Julie M Zito; Albert T Derivan; Christopher J Kratochvil; Daniel J Safer; Joerg M Fegert; Laurence L Greenhill
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-09-15       Impact factor: 3.033

9.  Effects of Alfaxalone or Propofol on Giant-Breed Dog Neonates Viability During Elective Caesarean Sections.

Authors:  Monica Melandri; Salvatore Alonge; Tanja Peric; Barbara Bolis; Maria C Veronesi
Journal:  Animals (Basel)       Date:  2019-11-13       Impact factor: 2.752

10.  Infectious Disease Risk Associated with Contaminated Propofol Anesthesia, 1989-2014(1).

Authors:  Andrés Zorrilla-Vaca; Jimmy J Arevalo; Kevin Escandón-Vargas; Daniel Soltanifar; Marek A Mirski
Journal:  Emerg Infect Dis       Date:  2016-06       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.